7th Mentored Paper (Fall 2022)

Topics

MPI7.1: What is the role of stress granules in disease?

 

MPI7.2: How do misfolded proteins contribute to neurodegenerative disease? (focus on one or two diseases: Huntington’s, Alzheimer’s, ALS, Creutzfeldt-Jakob, etc.)

 

MPI7.3: How is heartbeat regulated by ion channels?

 

MPI7.4: What is the current research examining sensory, neurological, and/or cognitive difficulties for those who tested positive for COVID-19?

 

MPI7.5: How can nanotechnology help in reaching UN sustainability goals?

 

MPI7.6: What is flash graphene, and what applications can it be used in?

 

MPI7.7: What role do extracellular vesicles play in the pathobiology and immune evasion of malignant diseases?

 

MPI7.8: What are the current health inequities and social determinants which lead to diagnostic delays in gynecological diseases?

 

MPI7.9: Do phytoestrogens (plant-based compounds that mimic estrogen) such as soy, tofu, beans and berries, play a role in estrogen-dependent diseases, such as endometriosis?

 

MPI7.10: How can Plant-Based Dietary Index (PDI) metrics relate to health outcomes?

 

MPI7.11: What is the relationship between protein content claim (protein quality and protein content) and nutrient intakes of Canadians?

 

MPI7.12: How can inositol be used as an effective treatment for PCOS?

 

MPI7.13: Can the implementation of a machine learning model within a non-knowledge-based clinical decision support system be useful for front-line workers in psychiatry?

 

MPI7.14: How can innovative technologies in AI create a gold standard for disease modelling within psychiatry?

 

MPI7.15: What types of data (passive or actively gathered data) are useful for machine learning models in psychiatry (systematic/literature review)?

 

MPI7.16: Why do some people not vaccinate against deadly diseases?

 

MPI7.17: What are the most effective ways to engage patients and families in hospital activities (e.g., quality improvement, research, and strategic planning)?

 

MPI7.18: Is there a benefit in using combinatory therapies in treating heterogeneous cancers like glioblastoma?

 

MPI7.19: Highly evolving cancers are often treatment refractory due to the cancer being mutagenic. How can we use mutation and epigenetic mutation clocks to evaluate the mutational course of specific cancers?

 

MPI7.20: How can we adopt and alter the immune system to attack cancer?